Danaher Corporation $DHR Shares Purchased by Perennial Investment Advisors LLC

Perennial Investment Advisors LLC boosted its stake in Danaher Corporation (NYSE:DHR) by 21.1% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,344 shares of the conglomerate’s stock after buying an additional 582 shares during the quarter. Perennial Investment Advisors LLC’s holdings in Danaher were worth $661,000 as of its most recent filing with the SEC.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of Danaher by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock valued at $12,004,424,000 after buying an additional 788,499 shares during the period. Price T Rowe Associates Inc. MD boosted its position in Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after buying an additional 612,154 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Danaher by 0.6% in the second quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock worth $2,697,800,000 after acquiring an additional 81,670 shares in the last quarter. Generation Investment Management LLP grew its stake in Danaher by 56.2% during the 2nd quarter. Generation Investment Management LLP now owns 4,965,646 shares of the conglomerate’s stock valued at $980,914,000 after purchasing an additional 1,787,522 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock worth $965,259,000 after purchasing an additional 1,450,703 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 2.4%

DHR stock opened at $225.75 on Wednesday. The stock has a market cap of $159.46 billion, a PE ratio of 46.55, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. The firm’s 50-day simple moving average is $206.70 and its 200 day simple moving average is $201.47. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $258.23. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same quarter last year, the business earned $1.71 earnings per share. Danaher’s revenue was up 4.4% compared to the same quarter last year. As a group, sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s payout ratio is presently 26.39%.

Analyst Ratings Changes

Several analysts recently issued reports on DHR shares. Rothschild Redb cut shares of Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Guggenheim restated a “buy” rating and issued a $250.00 target price on shares of Danaher in a research note on Wednesday, July 23rd. JPMorgan Chase & Co. increased their target price on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft raised their price target on shares of Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Finally, Bank of America lowered their price objective on shares of Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. Eighteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. The trade was a 59.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Teri List sold 2,778 shares of the business’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 29,728 shares of company stock valued at $6,448,990. Corporate insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.